Seelos therapeutics announces 1-for-30 reverse stock split

New york , nov. 24, 2023 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel) ("seelos" or the "company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its board of directors approved a 1-for-30 a reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. eastern time on tuesday, november 28, 2023.
SEEL Ratings Summary
SEEL Quant Ranking